Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 531
- Registration Number
- NCT04401748
- Locations
- 🇺🇸
Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 223727, Dallas, Texas, United States
🇺🇸UPMC Hillman Cancer Ctr /ID# 223201, Pittsburgh, Pennsylvania, United States
🇨🇳China Medical University Hospital /ID# 218987, Taichung, Taiwan
A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Celgene
- Target Recruit Count
- 22
- Registration Number
- NCT04336982
- Locations
- 🇺🇸
Local Institution - 104, San Francisco, California, United States
🇺🇸Local Institution - 103, Boston, Massachusetts, United States
🇨🇦Local Institution - 201, Toronto, Ontario, Canada
A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-06
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1
- Registration Number
- NCT04298918
- Locations
- 🇦🇺
Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 76
- Registration Number
- NCT04284787
- Locations
- 🇺🇸
Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
🇺🇸University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
- Conditions
- Interventions
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 166
- Registration Number
- NCT04285567
- Locations
- 🇫🇷
CHU de Caen, Institut d'Hématologie de Basse-Normandie, Caen, France
🇫🇷Hopital Robert Debre; Hematologie Clinique, Reims, France
🇺🇸Oncology & Hematolgy Associates of SW Va Inc. - Roanoke, Roanoke, Virginia, United States
Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Recurrent Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory Burkitt LymphomaHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Burkitt LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Interventions
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Registration Number
- NCT04285268
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy
- Conditions
- Interventions
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2022-01-04
- Target Recruit Count
- 157
- Registration Number
- NCT04282811
- Locations
- 🇮🇹
Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto, Bari, Italy
🇮🇹Aou Arcispedale Sant'Anna - Cona (Fe) - Uoc Ematologia E Fisiopatologia Della Coagulazione, Cona, Ferrara, Italy
🇮🇹Aon Ss. Antonio E Biagio E C. Arrigo - Alessandria - Soc Ematologia, Alessandria, Italy
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 366
- Registration Number
- NCT04278768
- Locations
- 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT04277442
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
- Conditions
- Interventions
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 2
- Registration Number
- NCT04274907
- Locations
- 🇺🇸
Arizona Oncology Associates, PC-HOPE (Rudasill) /ID# 216984, Tucson, Arizona, United States
🇺🇸St Jude Hospital dba St Joseph /ID# 212360, Santa Rosa, California, United States
🇺🇸Icri /Id# 217071, Whittier, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.